Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the national Class 1 innovative drug TQH3906 “TYK2/JAK1 JH2 allosteric inhibitor” independently developed by the Group has recently completed phase II clinical trials for moderate to severe plaque psoriasis (PsO). The study results showed that all dosage groups of TQH3906 showed good safety and tolerability, and reached the main end point of the Phase II study.

Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the national Class 1 innovative drug TQH3906 “TYK2/JAK1 JH2 allosteric inhibitor” independently developed by the Group has recently completed phase II clinical trials for moderate to severe plaque psoriasis (PsO). The study results showed that all dosage groups of TQH3906 showed good safety and tolerability, and reached the main end point of the Phase II study.